Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Regions of papilloma virus E1 helicase involved in E1 oligomerization

a helicase and papilloma virus technology, applied in the field of papilloma virus e1 helicase involved in e1 oligomerization, can solve the problems of no effective antiviral treatment for hpv infection, no treatment of all viral particles, and high cost incurred or uncomfortable side effects

Inactive Publication Date: 2005-12-29
BOEHRINGER INGELHEIM CANADA LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] Further, localization of this region by the Applicant provides a potential new therapeutic target in the treatment of PV infections. It is therefore a further advantage of the invention to provide a screening method for identifying agents capable of modulating this new target and a system to select at least one such agent capable of interfering with PV DNA replication.
[0020] The present invention refers to a number of documents, the content of which is herein incorporated by reference. SUMMARY OF THE INVENTION
[0021] The present invention concerns the elucidation of some of the steps necessary for initiating papillomavirus DNA replication. More particularly, the role of E1 protein (a.a. 1-649)(SEQ ID No. 1) in viral DNA replication. Most particularly the requirement for PV E1 protein oligomerization, as a step preceding viral DNA unwinding and DNA replication.
[0022] Therefore, in accordance with the first embodiment of the present invention, there is provided an amino acid sequence comprised within the PV E1 protein region A delineated by amino acids 352 and 439, and any derivative variant or fragment thereof, necessary for the oligomerization of the E1 protein. This amino acid sequence is capable of self-association and of associating with the full length E1 protein and any derivative, variant or fragment thereof comprising the sequence of this invention.
[0023] In accordance with this first embodiment, there is provided an amino acid sequence necessary for the oligomerization of PV E1 protein. This amino acid region or domain, as numbered from the amino acid sequence of human papilloma virus (HPV) type 11, is delineated by amino acids 352 and 439. Any derivative, variant or fragment of this amino acid region capable of demonstrating the same structural and functional activity is within the scope of this invention. In a particular aspect of this first embodiment, the amino acid sequence is further delineated by amino acids 352 and 432. In a more particular aspect of this first embodiment the amino acid sequence is further delineated by amino acids 352 and 417. The Applicant was the first to identify this domain comprised within the PV E1 protein as the amino acid sequence necessary for E1 protein oligomerization, which is an essential prerequisite step in the initiation of viral DNA replication. Therefore, in a specific aspect of this first embodiment, the amino acid domain of this invention delimited by amino acids 353 to 438 of the PV E1 protein. More particularly, the amino acid domain of this invention is as defined by SEQ ID NO. 2.
[0024] The Applicant was also the first to recognize that the elucidation of this amino acid sequence provides a new therapeutic target for the control, prevention, elimination and treatment of PV infections in mammals.

Problems solved by technology

These treatments are not completely effective in eliminating all viral particles and there is either a high cost incurred or uncomfortable side effects related thereto.
In fact, there are currently no effective antiviral treatments for HPV infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Regions of papilloma virus E1 helicase involved in E1 oligomerization
  • Regions of papilloma virus E1 helicase involved in E1 oligomerization
  • Regions of papilloma virus E1 helicase involved in E1 oligomerization

Examples

Experimental program
Comparison scheme
Effect test

example 1

Yeast Strain, Media, and Genetic Methods

[0133]Saccharomyces cerevisiae strain Y153 (MATa leu2-3, 112 ura3-52 trp1-901 his3-Δ200 ade2-101 gal4Δgal80Δ URA3::GAL-lacZ LYS::GAL-HIS3) was used for yeast two-hybrid analysis (Durfee et al., 1993, Genes. Dev. 7:555-569). Transformation of yeast strain Y153 was performed using the LiAc method essentially as described in the Clontech Matchmaker Library Protocol. Cells that were co-transformed with a combination of two plasmids were selected at 30° C. for 3 to 5 days on SD medium (described by Sherman et al. 1979, Methods in Yeast Genetics, Cold Spring Harbor, N.Y.) lacking leucine and tryptophan but supplemented with the other required amino acids.

example 2

β-Galactosidase Assays

[0134] Transformed yeast cells were pre-grown in liquid SD medium lacking leucine and tryptophan and then used to inoculate YPD (Sherman et al. Supra) cultures. These cultures were grown at 30° C. until they reached an optical density of approximately 0.6 at 600 nm (OD600). Cells were then harvested, washed and permeabilized by two cycles of freezing (liquid nitrogen) and thawing. β-galactosidase activity was then measured spectrophotometrically (at 578 nm) using the substrate chlorophenyl-red-β-D-galactopyranoside (CRPG, Boehringer Mannheim) as described in the Clontech Matchmaker Library Protocol. Enzymatic activity was calculated using the equation: Miller unit=(1000×OD578) / (elapsed min×1.5 ml culture×OD600).

example 3

Plasmid Constructions

A. Plasmids for In-Vitro Transcription / Translation

[0135] The constructs and the primers for amplification are summarized in Table 1.

[0136] Plasmids used for synthesis of HPV-11 E1 and E2 in vitro were derived either from pCR3 (Invitrogen, CA) or from pTM1 (obtained from Bernard Moss, NIH). In these plasmids, the encoded protein can be expressed in vitro from the T7 promoter located upstream of the open reading frame (ORF). When used in a coupled transcription / translation system (TNT Coupled Reticulocyte Lysate System, Promega), plasmids derived from pTM1 directed the synthesis of higher levels of proteins. Presumably, it is because this plasmid encodes the EMCV IRES (encephalomyocarditis virus internal ribosome entry site), which stimulates translation (data not shown).

[0137] To construct pCR3-E1 and pCR3-E2, the entire HPV-11 E1 and E2 ORFs were amplified separately by polymerase chain reaction (PCR), though any method capable of amplifying DNA is suitable...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

There is provided an amino acid sequence comprised within the PV E1 protein region A delineated by amino acids 352 and 439, and any derivative variant or fragment thereof, necessary for the oligomerization of the E1 protein. This amino acid sequence is capable of self-association and of associating with the full length E1 protein and any derivative, variant or fragment thereof comprising the sequence of this invention. A specific aspect of this first embodiment, the amino acid domain of this invention delimited by amino acids 353 to 438 of the PV E1 protein. More particularly, the amino acid domain of this invention is as defined by SEQ ID NO. 2. There is also provided a cross-linking assay to directly measure the level of oligomerization (or inhibition thereof) of the E1 protein. In accordance with a fourth embodiment of this invention, there is provided a N-terminally truncated E1 protein. More particularly, one aspect of this fourth embodiment encompasses the E1 protein delimited by amino acid 72 to 649 (SEQ ID NO. 78).

Description

RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 10 / 339,268, filed Jan. 9, 2003 which is a division of U.S. Ser. No. 09 / 744,202, now abandoned, filed Jan. 19, 2001, which is a national stage application of PCT / CA99 / 00657, filed on Jul. 20, 1999, which claims the benefit under 35 USC 119(e) of U.S. Provisional Application Ser. No. 60 / 093,626, filed on Jul. 21, 1998, the disclosures of all of which are incorporated by reference in their entireties.FIELD OF THE INVENTION [0002] The present invention relates to an amino acid sequence comprised in the papilloma virus E1 protein, necessary for the homo-oligomerization of the E1 protein. This oligomerization, is an essential step in the initiation of viral DNA replication. Further, the invention discloses a screening method and a screening system capable of selecting agents capable of interfering with this protein-protein interaction. Moreover, the invention further relates to a system for the selection of ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/50A61K38/00A61K39/00C07K14/025C12N15/09C12N15/37C12Q1/68C12Q1/70G01N33/15G01N33/53G01N33/539G01N33/566G01N33/569G01N33/573
CPCA61K38/00A61K39/00C07K14/005C12N2710/20022G01N2500/00G01N33/56983G01N33/573G01N2333/025C12Q1/708
Inventor ARCHAMBAULT, JACQUES
Owner BOEHRINGER INGELHEIM CANADA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com